Analysed ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) News Sources
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
17-04-2026
yahoo.com
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
16-04-2026
yahoo.com
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
15-04-2026
yahoo.com
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
30-03-2026
yahoo.com
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
09-03-2026
yahoo.com
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
04-03-2026
yahoo.com
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
02-03-2026
yahoo.com
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
30-01-2026
yahoo.com
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
21-01-2026
yahoo.com
What is the current price of ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ)?
The current price of ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) is $4.855.
ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) since the previous trading day is $-0.295.
ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) since the previous trading day is -5.7282%.
What is the most recent average sentiment score for ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ)?
The most recent average sentiment score for ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ)?
The most recent sentiment for ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ) is .
SEC-8K** Filing Available For ALTERITY THERAPEUTICS-ADR (ATHE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.